Merck, Eisai face late-stage trial setback (MRK:NYSE)
Summary
Merck (MRK) stock is in focus as the company and Eisai (ESALF) announce a setback in a late-stage trial for two Keytruda-based regimens in kidney cancer. Read m...
Description
Merck (MRK) stock is in focus as the company and Eisai (ESALF) announce a setback in a late-stage trial for two Keytruda-based regimens in kidney cancer. Read m...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source